Preclinical testing of Burkitt lymphoma and DLBCL cell lines with MTI monotherapy or MTIs in combination with HDAC inhibitors shows enhanced cell apoptosis versus single-agent HDAC and substantial inhibition of cell cycle progression, primarily due to cell cycle arrest at G0/G1 (49–51). This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.